↓ Skip to main content

In vitro potency of amikacin and comparators against E. coli, K. pneumoniae and P. aeruginosa respiratory and blood isolates

Overview of attention for article published in Annals of Clinical Microbiology and Antimicrobials, January 2016
Altmetric Badge

About this Attention Score

  • Above-average Attention Score compared to outputs of the same age (51st percentile)

Mentioned by

twitter
4 tweeters

Citations

dimensions_citation
20 Dimensions

Readers on

mendeley
42 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
In vitro potency of amikacin and comparators against E. coli, K. pneumoniae and P. aeruginosa respiratory and blood isolates
Published in
Annals of Clinical Microbiology and Antimicrobials, January 2016
DOI 10.1186/s12941-016-0155-z
Pubmed ID
Authors

Christina A. Sutherland, Jamie E. Verastegui, David P. Nicolau, Sutherland, Christina A, Verastegui, Jamie E, Nicolau, David P

Abstract

The purpose of this study was to define the potency of amikacin and comparator agents against a collection of blood and respiratory nosocomial isolates implicated in ICU based pulmonary infections gathered from US hospitals. Minimum inhibitory concentrations of amikacin, aztreonam, cefepime, ceftazidime, ceftolozane/tazobactam, ceftriaxone, ciprofloxacin, imipenem, meropenem, piperacillin/tazobactam and tobramycin were tested against 2460 Gram-negative isolates. Amikacin had 96 % susceptibility against the combined E. coli and K. pneumoniae isolates and 95 % susceptibility against P. aeruginosa. Ninety-six percent of all of isolates tested were susceptible (i.e., MICs ≤16 mg/L) to amikacin by current laboratory standards which demonstrates a high level of activity to combat infections caused by these organisms including ESBL, MDR, β-lactam and fluoroquinolone resistant strains. Moreover, 99 % of all organisms had amikacin MICs ≤64 mg/L. Overall, these data highlight the continued potency of amikacin and suggest that the achievable lung concentrations of approximately 5000 mg/L with the administration of the amikacin by inhalation (Amikacin Inhale, BAY41-6551) will exceed the MICs typically observed for P. aeruginosa, E. coli and K. pneumoniae in the hospital setting.

Twitter Demographics

The data shown below were collected from the profiles of 4 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 42 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 42 100%

Demographic breakdown

Readers by professional status Count As %
Student > Master 8 19%
Researcher 7 17%
Student > Bachelor 6 14%
Lecturer 3 7%
Student > Ph. D. Student 3 7%
Other 6 14%
Unknown 9 21%
Readers by discipline Count As %
Medicine and Dentistry 10 24%
Pharmacology, Toxicology and Pharmaceutical Science 5 12%
Agricultural and Biological Sciences 5 12%
Immunology and Microbiology 3 7%
Nursing and Health Professions 2 5%
Other 6 14%
Unknown 11 26%

Attention Score in Context

This research output has an Altmetric Attention Score of 2. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 23 September 2016.
All research outputs
#4,001,224
of 8,422,812 outputs
Outputs from Annals of Clinical Microbiology and Antimicrobials
#119
of 274 outputs
Outputs of similar age
#121,158
of 267,458 outputs
Outputs of similar age from Annals of Clinical Microbiology and Antimicrobials
#10
of 15 outputs
Altmetric has tracked 8,422,812 research outputs across all sources so far. This one has received more attention than most of these and is in the 50th percentile.
So far Altmetric has tracked 274 research outputs from this source. They receive a mean Attention Score of 3.6. This one has gotten more attention than average, scoring higher than 53% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 267,458 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 51% of its contemporaries.
We're also able to compare this research output to 15 others from the same source and published within six weeks on either side of this one. This one is in the 26th percentile – i.e., 26% of its contemporaries scored the same or lower than it.